Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup
Xconomy
AUGUST 11, 2020
The larger company agreed to pay $12 per share for Pfenex (NYSE American: PFNX )—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: LGND ) generates revenue from licensing deals and royalties paid by pharmaceutical companies that use technologies it develops or acquires for their own drug research.
Let's personalize your content